Summary of LongeVC’s Investments in Q1 and Q2

As we’re getting to the end of Q2, we prepared a quick summary of all the new additions to LongeVC’s investment portfolio. As a co-founder, Garri actively participated in the process of decision making, research and due diligence.

Below we present a list of the new startups LongeVC team backed in the first half of 2024:

Ani Biome: An agetech startup focused on gut health.

The company focuses on improving gut health using personalized naturally-derived molecules called AgeBiotics. Ani Biome uses advanced technology to assess clients' gut health and increase the production of beneficial substances in the gut to reduce inflammation. For more details, read LongeVC’s full announcement here.

Rubedo: Treatments for biological youth

Rubedo Life Sciences, a California-based biopharmaceutical company, has introduced the Alembic™ drug discovery platform to target pathological cells responsible for aging. The company has secured a $40M series A funding. Read more here.

HelixNano: Next-generation mRNA therapeutics

HelixNano envisions a future where treatments are affordable, progress is decentralized, and biology can be modified instantly. Concentrating on mRNA from first principles accelerates progress, making testing faster and more cost-effective. LongeVC’s announcement with more details here.

CatenaBio: Development of novel therapeutics

CatenaBio is a biotech company advancing personalized medicine by developing therapeutics that can target specific cells without altering their genetic makeup. More information can be found here.